About ABBV-744 as a potential therapeutic option for aggressive cancers
In Section C, members will get ABBV-744 and oral navitoclax. In Segment D, individuals will acquire ABBV-744 and ruxolitinib. Participants will obtain treatment until eventually sickness progression or even the contributors are unable to tolerate the study drugs.Celastrol was identified like a Myb inhibitor that suppressed C/EBPβ action and repres